Therapeutic potential of FGF21 in cardiorenal syndrome

Int J Cardiol. 2016 Jul 1:214:70-1. doi: 10.1016/j.ijcard.2016.03.142. Epub 2016 Mar 26.

Authors

Fanghua Li¹, Chengyuan Tang¹, Zheng Dong²

Affiliations

¹ Institute of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Institute of Nephrology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Department of Cellular Biology & Anatomy, Medical College of Georgia at Augusta University, Charlie Norwood VA Medical Center, Augusta, GA 30912, United States. Electronic address: zdong@gru.edu.

PMID: 27057978
DOI: 10.1016/j.ijcard.2016.03.142

No abstract available

Keywords: Cardiorenal syndrome; Dylipidemia; FGF21; Inflammation; Oxidative stress.

MeSH terms

Anti-Inflammatory Agents / metabolism*
Cardio-Renal Syndrome / drug therapy
Cardio-Renal Syndrome / metabolism*
Fibroblast Growth Factors / metabolism*
Humans
Kidney / metabolism
Oxidative Stress / drug effects

Substances

Anti-Inflammatory Agents
fibroblast growth factor 21
Fibroblast Growth Factors